POPULARITY
2 episodes with dxd
2 episodes with dxd
2 episodes with dxd
2 episodes with dxd
2 episodes with dxd
12 episodes with dxd
On this episode of Beyond Multifamily, Amanda Cruise and Ash Patel interview Drew Dolan, fund manager at DXD Capital, a self-storage-focused CRE firm based in Albuquerque, New Mexico. Drew shares how his background in engineering and technical sales led to a pivot into development, and why he now prefers building over buying due to the greater margin for error and control over entitlements. He breaks down DXD's national development strategy, current projects in 20 states, and why fully entitled land is one of the most overlooked opportunities. Drew also shares insights on supply chain risks, market elasticity in self-storage, and how rising rates and housing stagnation impact demand. Drew Dolan Current role: Fund Manager at DXD Capital Based in: Albuquerque, New Mexico Say hi to them at: drew@dxd.capital or dxd.capital Get a 4-week trial, free postage, and a digital scale at https://www.stamps.com/cre. Thanks to Stamps.com for sponsoring the show! Post your job for free at https://www.linkedin.com/BRE. Terms and conditions apply. Try Huel with 15% OFF + Free Gift for New Customers today using my code bestever at https://huel.com/bestever. Fuel your best performance with Huel today! Join the Best Ever Community The Best Ever Community is live and growing - and we want serious commercial real estate investors like you inside. It's free to join, but you must apply and meet the criteria. Connect with top operators, LPs, GPs, and more, get real insights, and be part of a curated network built to help you grow. Apply now at www.bestevercommunity.com Learn more about your ad choices. Visit megaphone.fm/adchoices
In this episode of the Rainmaker Podcast, host Gui Costin welcomes Drew Dolan, co-founder and principal of DXD Capital, for a compelling conversation on data-driven development, investor relations, and building a specialized real estate platform. With over 20 years in real estate and a deep passion for ground-up development, Drew shares how he transitioned from technical sales into leading one of the most forward-thinking firms in self-storage.Founded in 2020, DXD Capital was built on the belief that self-storage is a real estate-driven asset class where location and timing are everything. By leveraging a proprietary analytics platform, Radius+, co-created by Drew's partner, DXD is able to assess rates, density, competition, and demographic trends with precision. This data-first strategy has helped DXD identify and develop prime self-storage projects across the U.S.—from Nantucket to Maui.Drew walks through the firm's capital strategy, explaining their evolution from a $63M LP fund to a flexible model incorporating both funds and one-off joint ventures with family offices. This structure allows DXD to cater to both high-net-worth individuals and large institutions, with a focus on customization, transparency, and performance. Drew emphasizes that communication is key—monthly updates, timely financials, and responsiveness help build trust with their 300+ investors.Internally, DXD runs a lean, focused operation with 30 employees spread across three main offices and remote locations near active projects. Slack and weekly check-ins are central to internal communication, while in-person retreats help maintain cultural connection. Drew also shares his leadership philosophy, centered around empowering others, encouraging ongoing learning, and hiring people who are better than him in key roles.From an IR standpoint, DXD recently expanded its team, bringing in professionals with strong relationship instincts and private equity backgrounds. Drew underscores that while industry knowledge can be taught, trust and human connection are what open doors. Their tech stack, including Juniper Square and HubSpot, helps them manage investor communication and track data, but Drew admits the most effective outreach still comes down to “hand-to-hand combat.”Tired of chasing outdated leads? Book a demo to see how Dakota Marketplace simplifies your fundraising process with accurate, up-to-date investor data.
In today's episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. In our exclusive interview, Dr Gerber discussed the evolving role of antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), focusing on findings from key clinical trials. He highlighted results from the phase 3 TROPION-Lung01 trial (NCT04656652), which demonstrated a modest improvement in progression-free survival with datopotamab deruxtecan-dlnk (Datroway), a TROP2-directed ADC, compared with docetaxel in patients with previously treated advanced NSCLC. He also emphasized the toxicity profile of TROP2-directed ADCs, particularly gastrointestinal toxicities and myelosuppression. Dr Gerber also reviewed the phase 2 HERTHENA-Lung01 trial (NCT04619004) evaluating patritumab deruxtecan in patients with EGFR-mutant NSCLC and the phase 2 DESTINY-Lung02 trial (NCT04644237) assessing fam-trastuzumab deruxtecan-nxki (Enhertu) in those with HER2-mutant NSCLC. Dr Gerber reflected on the shared DXd payload of these ADCs, highlighting its implications for toxicity and efficacy, as well as open questions regarding treatment sequencing and resistance mechanisms.
Home Theater News 10.16.24 links and notes: Join our home theater community at AVNirvana.com. Build relationships with other Home Theater Enthusiasts and talk shop about speakers, processors, projectors, TVs, and more. We look forward to having you join our community! *Buy a MediaLight MK2 v2 Bias Light Kit* Buy: https://www.biaslighting.com/products/medialight-mk2-flex-6500k-cri-98-bias-lighting?rfsn=6210737.cd199a&utm_source=refersion&utm_medium=affiliate&utm_campaign=6210737.cd199a *Link to Klipsch Flexus Core 200 Giveaway Contest at the Forum AVNirvana.com* https://www.avnirvana.com/threads/giveaway-time-enter-to-win-a-new-klipsch-flexus-core-200-soundbar.14267/ *Link to Buy Home Theaterology Coffee Table Book* Buy Direct: https://hometheaterology.net/ *Link to MediaLight MK2 v2 News Article* Link: https://www.avnirvana.com/threads/medialight-unveils-the-ultimate-mk2-v2-bias-light-new-features-and-first-impressions.14231/ *DISC DEALS on AMAZON* -Violent Night Blu-ray: https://amzn.to/3UbVWyv -Violent Night 4K: https://amzn.to/3U845nL -Better Watch Out Blu-ray: https://amzn.to/4dKq1fz -Krampus Blu-ray: https://amzn.to/4dMoDsQ -Krampus 4K Collectors by Shout Factory: https://amzn.to/4eJopUy *Gear Deal of the Week* SVS SB16-Ultra Subwoofer, $600 off: https://fave.co/4bOULLC SVS PB16-Ultra, $700 off Subwoofer: https://fave.co/3zGGQu5 *Forum Links* -For the latest disc reviews, go to: https://www.avnirvana.com/forums/blu-ray-media-reviews.12/ -For the latest news, including stories covered in this episode: https://www.avnirvana.com/forums/av-industry-news.6/ -To see the Top 20 Disc Releases of 2023, go to: https://www.avnirvana.com/threads/holiday-gift-guide-top-20-movie-discs-of-the-year.12847/ *PODCAST LINKS* -Subscribe to the podcast on Spotify: https://open.spotify.com/show/2XZc1WVL7gGazxGLiURw0E Subscribe to the podcast on Apple: https://podcasts.apple.com/us/podcast/av-nirvanas-home-theater-news-review-htnr/id1715862636 On this week's edition of the Home Theater News Review Podcast, - Episode 10.16.24 - MediaLight has released a new bias lighting kit (MK2 v2) that promises to enhance your viewing experience like never before. We'll dive into what's new and why it outshines cheap LED strips. Focal has launched a new wireless, active loudspeaker called Diva Utopia and Arendal Sound has announced a new line of speakers called the 1528. We talk about both and dig into what they're all about. Also on the Audio front we discuss Fasetto's Audio Cu audio over power line technology, Cambridge Audio's new EXA100 Integrated Amp and EXN100 Music Streamer, Qobuz's Introduction of DSD and DXD downloads, and iFi Audio's new Stealth Edition hip-dac 3. And to round things out, we jump into the world of TVs and talk about two big stories happening in the OLED segment, both of which may impact your wallet. Also, we reveal a big Klipsch Flexus Core 200 Soundbar Giveaway Contest! We'll tell you how to get a free extra entry to win right here on the podcast!! Please Note: AV Nirvana may make a small commission from affiliate links... thanks for your support!
Lunes 25 de marzo de 2024 Ya esta disponible MEDELLIN TECHNO PODCAST 208 Presentado por: DERAOUT Invitados: DxD aka Deadwalkman & Deraout Más información de DEADWALKMAN: www.facebook.com/deadwalkman/ Soundcloud: @deadwalkman Instagram: www.instagram.com/blcklts27/ beatport: https://www.beatport.com/es/release/dxd-ii/4437702 Artist List: - DxD - Radar - Procombo - Confidential Recipe - Reeko - Metapattern - Deadwalkman - Uncertain - Coyu - Hertz - Deraout - Dextro - Ben Sims _________________ Design: www.boldbravestudio.com __ #medellintechnopodcast #ravecode #technodemedellin #medellintechnofestival #medellin #techno #podcast #colombia #medellintechno #DxD #dxdtechno #gndrecords #deadwalkman
At the European Society for Medical Oncology (ESMO) 2023 Congress Aditya Bardia, MD, MPH, presented results from the TROPION-Breast01 trial, which is comparing a new antibody-drug conjugate, datopotamab-deruxtecan (dato-DXd), to doctors' choice of chemotherapy for inoperable or metastatic, hormone receptor-positive, HER2-negative breast cancer that had grown while being treated with hormonal therapy and also had been treated with chemotherapy. Listen to the podcast to hear Dr. Bardia explain: what an antibody-drug conjugate is the design of the TROPION-Breast01 study and the first results dato-DXd side effects how dato-DXd might fit into the current treatment landscape for metastatic breast cancer
In this JCO Article Insights episode, Davide Soldato interviews Dr. Jacob Sands, medical oncologist at Dana Farber Cancer Institute (Boston, MA) and Assistant Professor at Harvard Medical School, on their paper “First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01”. The interview offers a deep dive into the safety and efficacy data of this novel drug and puts these data in the context of the current treatment landscape of NSCLC and of the revolution that ADC are bringing into the oncology world. TRANSCRIPT Davide Soldato: Welcome to this JCO Article Insights episode for the October issue of Journal of Clinical Oncology. This is Davide Soldato, and today I will have the pleasure of interviewing Dr. Jacob Sands, co-author of the manuscript titled, “First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.” Dr. Sands is a Medical Oncologist working at Dana-Farber Cancer Institute in Boston and Assistant Professor at Harvard Medical School. His main field of research and clinical interests revolve around improving screening and diagnosis of lung cancer and also on developing novel therapeutic agents for this disease. So, welcome Dr. Sans, and thank you very much for accepting our invitation today. Dr. Jacob Sands: Happy to join. Thanks for having me. Davide Soldato: I just wanted to start with a very general question because I think that we are going to discuss a very important study and the manuscript that you co-authored is going to look at the safety and the efficacy of this novel ADC datopotamab-deruxtecan that is targeting TROP2. But I just wanted to have a little bit of context before starting to discuss the safety and efficacy data. So the population that was included in the study included more or less 60% of patients that received three or more lines of therapy and also 20% of patients who received five or more lines of therapy. So I think that this is a very particular population, especially considering that we are speaking about non-small cell lung cancer. And so I wanted to get from you like a general context, like what are the therapeutic options for these patients normally in clinical practice and what do we expect in terms of outcomes and in terms of toxicity? Dr. Jacob Sands: Yeah, so as you point out, this is a highly pretreated population in general, which is to say that they've really gotten the most effective lines of treatment up to this point. Now, we certainly do see some efficacy from some of the later lines of therapies in some patients, but inherently there is a decreasing response rate and decreasing durability of these responses as patients get further along in their treatment courses as far as lines of therapy. So it's generally considered to be a challenging clinical scenario, which is part of what makes the data that we're going to discuss, I think, so meaningful. Davide Soldato: Yeah, I think that especially if we look at the population that was included first, I think that the very particular thing is that included both oncogene-addicted and non-oncogenic addicted patients, and also the great majority of these patients received the most effective treatments that are available because they all received more or less immunotherapy and platinum-based chemotherapy, if I'm not mistaken. Dr. Jacob Sands: That's right. And that's an important distinction that you're drawing in the patients with oncogenic drivers and, of course, there's plenty of data with this compound with Dato-DXD in that population as well. But broadly speaking, in the non-oncogenic actionable alterations where they've gotten chemo-immunotherapy, those really are the most meaningful. Of course, docetaxel has been a long-standing second line that I'd say there is less and less enthusiasm about that as a line of treatment as we've seen some of these other more novel therapies that have just a better toxicity profile in particular, but also some with really durability that we don't quite see with docetaxel as well. And so once you're getting past that, you're really now reaching a bit deeper to then have something that is well tolerated and has efficacy. That's a setting where we really need it even more. Davide Soldato: So, going back to the results of the study, as we kind of pointed out, this was a very standard classic with a Bayesian design, phase I dose escalation and dose expansion study of this novel ADC datopotamab-deruxtecan. So I just wanted to go over with you and to provide our listeners a little bit with some data regarding the doses that were explored and then what were the doses that were selected for the expansion. And also to discuss a little bit the safety data. We were discussing the tradeoff between risk and benefit, especially in patients that are very pretreated, searching for these kind of sweet spots between the toxicity and the efficacy. So I just wanted to put in context a little bit the data that you reported in the manuscript. Dr. Jacob Sands: Yeah, that's right. So, like phase I's go, we started with a low dose at 0.27 milligrams per kilogram, and dose escalations occurred up to 10 milligrams per kilogram. The 10 milligram per kilogram dose did have toxicities that really made it not considered to be tolerable, and that mostly being mucositis and skin. And so it was then back down to 8 milligrams per kilogram. And then there was a dose expansion at 4, 6, and 8 milligrams per kilogram. The 4 and 6 milligram per kilogram doses had 50 patients enrolled within those cohorts and 80 patients within the 8 milligram per kilogram cohort to then get much more data, of course, for efficacy and tolerability within those levels. Ultimately, each of them really demonstrated some efficacy as well as general tolerability. The 6 milligram per kilogram dose was really the one selected overall for further testing and future trials based upon the data out of this one that we're going to discuss further. Davide Soldato: What were the main side effects that you observed in the trial? And particularly, do you think that there is some kind of special toxicity that should be looked at when using this novel type of ADC? Dr. Jacob Sands: Certainly there are some novel toxicities to really pay attention to. And maybe I'll just point out before diving into the toxicities, that this is in many ways chemotherapy. The antibody drug conjugates, as listeners probably know, are an antibody that has a linker bound to chemotherapy, what's called the payload. And in this case, it's a topoisomerase I inhibitor with the antibody, the TROP2. So the cells on the surface, when there's TROP2 expression, the drug binds to that, gets pulled into the cell and releases that chemotherapy intracellular, but it is still chemotherapy. And so some of the toxicities are things that we commonly see with chemotherapy drugs. Although, broadly speaking, I would say we're able to deliver higher doses of that chemo to the cells in this kind of targeted dosing of chemotherapy to give the chemo intracellular. Now, that being said, some of the toxicities that we see from this drug in particular that are a bit different is the stomatitis, mucositis. That is something that has occurred. Now, I've found that if it's really severe, then with a dose reduction that has really substantially improved any toxicities with future dosing. And at a 6 milligram per kilogram dose, a dose reduction to 4 milligram per kilogram is still within a dose range where we saw plenty of efficacy within the trial that we're discussing. That being said, if one can help patients tolerate it better, if it's more mild symptoms, if it's not severe, then that's better in maintaining that dose. And interesting things like ice chips at the time of infusion, so cold within the mouth, kind of like the cold caps to try to reduce alopecia at the time of infusion of the chemo may help some steroid rinses also can be helpful. But really these are things to help prevent stomatitis from being severe. It's harder when that occurs, then the treatment for improving it is a bit different. We do know, though, that that does improve with time. So even when it was severe with that infusion, it does improve as patients get further out from those doses. Of course, another one is dry eyes or irritation within the eyes. And if that is severe, then or even mild actually, I'd say when there's any known toxicity like this is to involve ophthalmology. Now, within this trial, ophthalmology was involved and patients had to get a baseline eye exam and they would get checked at different time points throughout the course of the trial. And so they were being monitored. I did not have anyone who needed to stop the drug because of this. The patient I had with the longest standing response to therapy did have some dry eye. It was not bothering him so much. And he had this real aversion to using eyedrops. It was very hard for him to make himself use these. But when I told him, “Look, if this gets worse, you might have to come off the trial, that it might not be our decision just by the way the trial describes it, if this gets worse.” And so for him, the fear of having to come off the drug was really the thing that helped him to then start using his eyedrops, which really helped to control that a bit more. And so that is something to monitor for. But the biggest thing really is interstitial lung disease. This is something that is a complex topic, I think because it's something that we need to be very aware of and monitor for. At the same time, a diagnosis of interstitial lung disease can be challenging. There really were not cases where we had pathologic confirmation of this diagnosis. These are clinical diagnoses in the cases on this. Now there was an adjudication committee that would review all of the data and come to a determination of whether this looked like drug related ILD or not. But for clinicians, when you see a patient whose scan shows some inflammatory markings or inflammatory appearing markings on a scan, we see that all the time with other drugs too. And so determining what is potentially incidental versus drug related, I think in most cases on a trial when we're unsure, we lean toward drug related. And in some cases there are reported out severe cases of drug related ILD. I think the really difficult thing that I'd want people to take away from all of this, though, the bottom line is, yes, we need to be very aware of the potential for drug related ILD while at the same time, we need to not reflex, just call things drug related ILD and really make sure that we're doing a workup when feasible rather than just that bottom line conclusion. We see it at a rate related to the drug, and I do think it's real. But we also need to, when treating individuals, try to identify any other potential etiology. I did have one patient that really looked absolutely classic for this diffuse drug related ILD that ended up ultimately really being what looked more like tumor progression in just a radiographic pattern that looked more like an inflammatory process than it did the way we would typically see cancer progression. And so this has really, for me, I think, highlighted this as a topic where I'm diving a bit more into that description. Davide Soldato: And I also think that in the population of lung cancer patients, as you were saying, this is even more complicated because frequently these are patients who had a history of smoking, who can have concomitant infections where progression is easier in the lung. If I think, for example, other ADC that have already been tested, for example, in breast cancer, it might be far easier to detect and to adjudicate an ILD to the drug that we are using compared to what could be, for example, for lung cancer patients. So if I understood correctly, the toxicity that in your opinion as a clinician, they are more complicated to treat, let's say on a more daily basis, are more stomatitis and inflammation, but maybe the one that you experience as potentially more severe are always related to lung toxicity. Dr. Jacob Sands: Well, I think the scary thing about the ILD is that we have higher grades of ILD, and this is a toxicity that then can become life threatening. When we see a grade I or a grade II ILD reported in numbers, where we see, okay, this looks like it's really happening, and then see some really higher grade toxicities, I think the concern amongst clinicians then is if they're seeing lower grade, which of those can potentially progress to those higher grade, which then becomes life threatening toxicities. Whereas dry eyes certainly can become a nuisance, we didn't see any blindness or something like this, and the stomatitis resolves as you hold the drug, and in some cases, really before the next cycle even comes, it's just more a matter of controlling the discomfort, which can be severe. I'm not minimizing that. I think that's why ILD stands out so much, is that that becomes a potentially life threatening thing. And to your point exactly, these patients with a smoking history on other drugs, we see these inflammatory findings. Now, in some cases, we know it can be from the drug. In other cases, we see it and know that it's essentially incidental. And I'll say to patients, “Hey, we see this. It's something we'll monitor on future scans, and these can wax and wane.” When you have a patient on a drug with a high attention towards something like ILD, there can be- what I'm cautioning against is a reflex attribution to that drug. In all cases. I'd urge clinicians to individually assess each of these patients to get a sense of whether they think that that's going on for that person, knowing that it's often not possible to say with 100% certainty in any of these cases. But we often see waxing and waning inflammatory findings. And in many of these patients with heavier smoking histories, in particular, there can be waxing and waning respiratory symptoms. So the question is, are there instances where there is what really is an incidental inflammatory findings and incidental respiratory waxing and waning that then suddenly we call a grade II? At the same time on the other part of that, if there is something that seems like it really may be drug related ILD, is doing that work up and really evaluating and diagnosing that before it progresses to a point that really there are severe symptoms. And it's kind of trying to do both of those things on the opposite ends of the spectrum that I'm speaking toward at the same time. Davide Soldato: Just on a personal note, do you think that, as we continue the development of these drugs that are associated potentially with lung toxicity, do you think that we also need to pay attention to the drugs that were immediately previously received by the patients? What I mean is, do you have the feeling that the previous treatment could potentially impact on the risk of developing this type of toxicity in the lung? Dr. Jacob Sands: I don't know that we yet have data to draw any real conclusions around that. But you raise an important question within this, and what potential toxicities could be related to prior treatments or synergy across those. Of course, we see inflammatory findings within the lungs and pneumonitis with prior immune-related therapies, and that it would be a good prompt to the question you're asking. And that in particular, we also see this in some of the targeted treatments, although not nearly to the same percentages. I don't know that we can draw conclusions from this. I would speculate that the mechanisms of action of each of these drugs are so different that I would not hypothesize real synergy in those toxicities. But it is certainly something to be aware of and an important question that you're raising. Davide Soldato: I think that, apart from the safety data that I think we dissected, the other end of the spectrum would be finding a drug that this very pre-treated population could still give us some efficacy data. So you already mentioned that, in the dose expansion cohorts, so 4, 6, and 8 milligrams, we had more or less signals of activity and of efficacy of these novel drugs. So the therapeutic options, as you were mentioning, are potentially docetaxel or other types of mono chemotherapy. But we know that the objective response rate is not that high, and that progression-free survival is not that long with these types of drugs. And potentially the safety profile could also be complicated in patients that are also pre-treated. So I just wanted to discuss a little bit the efficacy data and to see if there is really promise in this type of delivery of chemotherapy as you were saying with the ADC. Dr. Jacob Sands: We saw response rates of about 25% across all three of those cohorts. The manuscript outlines the 4, 6, and 8 milligram cohorts within a chart showing the efficacy outcomes. And really it's around 25% across the three of those, which in this patient population, as we've discussed, heavily pre-treated, to have a response rate of 25% is really quite promising that there really is a substantial treatment effect. On top of that, we also see a duration of response of really around 10 months. So, in the patients that are having a response, there really is some durability. Now, it's tragic that 10 months is considered durable within this population and it really highlights the ongoing need for further drug development because I don't think anyone would say that 10 months is enough, we need dramatically better. But within the context of what we currently have, a 10-month duration of response is really quite meaningful and a response rate of 25%. Now, it also describes a disease control rate. And I always have to put a little asterisk to this. I think we see this increasingly - the disease control rate being reported - and it always looks quite a bit better than the response rate. And that's essentially incorporating stable disease. And although I would never claim that everybody with stable disease is truly benefiting from a drug, across all of the studies where this is reported out, there is a spider plot which really highlights a number of patients that are not considered responders, but with responses, a handful of them beyond six months of disease control, even though they're not considered responders, and one of them beyond a year with still ongoing disease control. So, even within that stable disease group, I'd say there are some who are really clinically benefiting from the drug, which is to say that really, even beyond the 25% response rate, we are seeing some others that are truly benefiting from this. Davide Soldato: Yes, and I also think that for these patients, especially when they can develop very rapidly symptoms that can potentially also impact quality of life, having a drug that achieves this level of stability - with maybe no deterioration in clinical symptoms - I think that it's still probably a very meaningful objective to obtain for this type of population. Of course, I think that with future studies we will also have probably health-related quality of life data that will tell us more about the impact of this type of drug in this setting. But I still think that this could be potentially a relevant endpoint, even if we don't achieve what we officially consider as a response as per resistor criteria. So I think that we have talked a little bit about the efficacy data. So, we are kind of entering a novel area where more and more ADCs are being tested, are being included in clinical practice. For example, if I think about breast cancer, we already have two that are approved that can be used, the same in bladder cancer. So, as you participated in this phase one trial, I just wanted to have your opinion: if you think that, in the future, we are going to evolve completely towards this type of delivery of chemotherapy, using what we call now "smart drugs" in terms of delivery of these cytotoxic agents. Dr. Jacob Sands: It'll be interesting to see. We certainly will see other generations of ADCs. I mean, I think we're really just at the beginning with this technology. We certainly have now a very solid foundation to build upon, where we have effective targets and effective payloads. We've highlighted some of the toxicities we're seeing from that. Also, I'd highlight within this drug with TROP2, the amount of expression has not seemed to really be a driver in this. And some of that may be the bystander effect, which I'd call a real benefit of the drug, where the payload as a drug goes through apoptosis and lysis, that payload that releases then into the surrounding- toward the surrounding cells is membrane permeable and crosses into other cells, leading to potentially more efficacy. That technology in itself, I'd say, is something that we may see incorporated further into next generations of ADCs. Whether there can be improvements in preventing toxic drug in other sites like the stomatitis, for example, with newer generations that evolve from this, we'll see. I don't know that I would anticipate all chemotherapy ultimately going through ADC technology, but I certainly believe that this is the beginning of what I would call a whole new class. But would future cytotoxic treatment happen more so through ADC than just broad circulating payloads? If we can call it that. And I certainly think we'll see a lot more development like that. But you know, we may see other ways of developing the cytotoxic drugs in other forms of delivery as well. It'll be exciting to see as we go forward. Davide Soldato: I also think that one of the major challenges that we probably will have to deal with, in probably not so long, is also the sequencing of these types of agents. We are starting to have, as I was saying, accumulating data regarding the efficacy of these drugs. And some of them share either the same payload or they target the same antigen on the cell. And so, do you think that we will need as a new line of research to really go into the field of cross resistance when we are using and trying to sequence these types of novel agents? Dr. Jacob Sands: We're seeing that across various tumor types. I mean, to stick with lung in particular and small cell lung cancer, we've seen DLL 3 really be a demonstrated target for small cell lung cancer. And now we have a handful of drugs being developed that target DLL 3. How would we potentially utilize those drugs? In what orders and which ones over others is going to be an area for discussion, much like the area you're raising here, where we see TROP2 directed treatments. And so which one would you choose? On top of the fact that there are other targets, in this case, we're talking about TROP2, but of course, there's HER3 that we've seen, and especially when we're talking about an EGFR population, EGFR mutation population, we've seen good efficacy with this TROP2 antibody drug conjugate, as well as the HER3. And so how would we order those? And they both are using the same payload. If we're talking about both of the deruxtecan compounds, this is going to take some sorting out. I think with time, it'll be tough. I don't know if we'll end up seeing head to head studies in this or if this is going to end up being shaped more by expert committees and their descriptions. But I imagine we'll see some heterogeneity in the treatment pathways at different centers just based upon preferences and familiarity with these different drugs. Of course, assuming that they all end up ultimately being approved and then that efficacy and tolerability that we're seeing continues to pan out in future trials. Davide Soldato: So we were mentioning before that there is a very big line of development for this novel ADC. And I think that there are also some trials that are exploring the role of data DXD so the datopotamab-deruxtecan in lines where patients have received less therapy or in combination with other agents. So I wanted to ask you if you could give us some insights regarding the ongoing trials, if you know about them. And also what do you think could be the area of a met need where this drug could potentially give the most effect? Dr. Jacob Sands: It'll be interesting to see. In the first line setting we have TROPION-Lung07 and TROPION-Lung08. These are studies with PDL-1 expression of less than 50% or greater than or equal to 50%, the greater than equal to 50% being plus pembrolizumab versus pembrolizumab alone. The less than 50% essentially being an incorporation with or instead of chemotherapy along with the platinum-based therapy plus pembro. And so that one is a more complicated three-arm study. Now, essentially what this is looking at is incorporating this antibody drug conjugate in place of chemotherapy for potential tolerability when given concurrently with the platinum and pembro. Whether or not we'll see some synergy with the chemo and the pembro, I guess I would hypothesize that we would likely see at least similar to when giving the chemotherapy, or at least that's the hypothesis driving the trial design. If anything, whether we note improved tolerability relative to those getting, I'd say the carboplatin component, because certainly within non-squamous, non-small cell, pemetrexed is generally very well tolerated. And so that's a bit tougher to beat out from a toxicity standpoint. The trials are really designed based upon the efficacy that we've seen from this trial you're pointing out. I think by the time that this podcast is heard, we'll have the data from TROPION-Lung01 that'll be reported out as well in the second line setting versus docetaxel as that data is near release. These are areas for ongoing attention, certainly. Davide Soldato: Thank you, Dr. Sands, for being with us today. This concludes our episode of JCO Article Insights. We discussed with Dr. Sands the results of the manuscript titled, “First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.” This is Davide Soldato. Thank you for your attention and stay tuned for the next episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
DEATH X DESTINY is a new band from Jonny McBee of The Browning and Moon McBee.- Join the community: JOINVideo of this episode is available for members only!Please support the podcast and guest by clicking the links down below: - Listen to DEATH X DESTINY- Follow on Instagram: Moon // Jonny McBee- Join the Burn This World Discord: Discord - Buy BLEGH COFFEE
CFTROU 0159: The Power Of The Neighborhood Church: A Conversation With Pastor Freddy T. Wyatt When essential foundational blocks in local neighborhood churches are in place, churches get healthy and things flourish! Welcome back as we continue with our series on the Power of the Neighborhood Church, today, with our guest, Pastor Jay Strother. He is the pastor at The Church at Station Hill and a part of the Brentwood Baptist Church family of churches. He's an influential speaker, writer, thinker, strategist, and incredible preacher. Tune in to hear from Pastor Jay about the story behind their church and the larger role he plays. He shares with us the strategy they implement to reach their local neighborhoods and how they navigate the different communities through their eight different campuses across Tennessee. They have a heart to strengthen and encourage the neighborhood churches, along with other like-minded Gospel churches, and they want to ensure Godly leadership that is crystal clear on the Gospel! Don't miss out on this great conversation with Jay, in another episode of Church, for the Rest of Us! Key Points: Jay shares his, and his team's, experience at the Church for the Rest of Us conference. More about Pastor Jay, his family, and the story behind their neighborhood church. Jay shares more about his role in his neighborhood church and in the larger church family. The strategy they use to reach their local neighborhood and community: Disciples multiplying Disciples (DxD). The four ways they go about their DxD strategy. How they differentiate their strategy amongst their campuses and Examples of unique things happening at and through the different neighborhood churches. Their mission at The Church at Station Hill. The importance of healthy neighborhood churches. What the neighborhood church means to Jay and his family. Advice on how to re-engage in your community: get outside the walls of your church! Bible passages that stand out to Jay in the incarnational neighborhood idea. He elaborates on why they, as a team, have been focusing on Acts 14. CFTROU 0163: The Power of the Neighborhood Church Series: Healthy Neighborhood Churches Grow! with Jay StrotherClick To Tweet — we call it DxD for Disciples multiplying Disciples. Our goal is to engage every single member of our church as a participant and not as a spectator" username="jaystrother"]We lead with the campus identity, the community identity, first, because we just want to be the hands and feet of Jesus in that local community.Click To TweetOur mission statement is: Engaging the whole person, with the whole Gospel of Jesus Christ, any time, anywhere, with anybodyClick To Tweet Links Mentioned in Today's Episode: Jay Strother on Twitter Thirty Years That Changed the World The Church at Station Hill Jimmy on Twitter Leslee on Twitter Family Church Network Family Church on Facebook Family Church on Instagram Church for the Rest of Us on Twitter Get podcast updates delivered to your inbox. Subscribe for free and never miss out on an episode of Church for the Rest of Us. Subscribe via Email iTunes Google Play Stitcher RSS If you like us, rate us or leave a comment below. Hopefully, this episode has given you principles, strategies, and ideas that you can implement right now with the resources you have. If so, can you let others know? The best way to do that is to rate the podcast on iTunes or Stitcher and leave us a brief positive review! This will help us place the podcast in front of more pastors and ministry leaders. It also lets us learn from you. Thank you for taking the time to get the word out about Church for the Rest of Us.
Today, you'll know why self-storage is a data-driven industry and how to seize the best opportunities with Drew Dolan. Start listening to learn more about how he manages his funds and investments, the value of risk mitigation, and why mistakes are essential to your overall success. Check this episode!WHAT TO LISTEN FOREffects of having new investors entering the self-storage industryHow you should look at your investments and become a good investorWhy it's important to be cautious and knowledgeable about business risks2 things to add to your criteria for selecting team membersWhat you need to implement to find success in self-storageABOUT DREW DOLANOver his 20-year career in development and construction, Drew has focused on deal structure, debt, and capital procurement and management. He has raised over $500 million and placed over $1 billion in debt for real estate investments. As fund manager and Principal at DXD, Drew created the fund structure, oversaw the capital raise for DXD Self Storage Fund I, which launched in 2020 and exceeded the goal ending with $53 million, and placed $50 million in debt in the first year. Drew has been quoted in the Wall Street Journal and New York Times as an expert in the self-storage industry. Previously, Drew was Fund Manager For Titan Development Real Estate Fund I, a $112 million fully-discretionary fund focused on ground-up development. Before becoming Fund Manager, he was President of Titan Development. Drew is currently a member of YPO, active on his ULI Council, and was formerly on NAIOP's national board. He holds a BS in Industrial Engineering from Arizona State University. CONNECT WITH DREWWebsite: DXD CapitalCONNECT WITH USWebsite: https://www.selfstorageinvesting.com/Facebook: https://www.facebook.com/selfstorageinvestingTwitter: https://twitter.com/SelfStorageGuyLinkedIn: https://www.linkedin.com/in/scottameyers/Youtube: https://www.youtube.com/user/SelfStorageInvestingInstagram: https://www.instagram.com/self_storage_investing/Subscribe so you never miss a NEW episode! Leave us an honest rating and review on Apple Podcast.
Are you wondering if self-storage investment is still as good as advertised amidst the surging inflation? Let's look into the data as to how self-storage does in different economic cycles, and Cory Sylvester joins the show to walk us through it. Don't miss this opportunity to learn what demand drivers are and how to achieve cash flow even at increasing rates!WHAT TO LISTEN FORWays to approach the marketplace in the face of recessionEffects of inflation on the demand for self-storage facilitiesHow you can utilize the third-party management as an investorReasons to go after developmental opportunities in a changing economic cycleWhat high rental rates and square feet per capita means for the self-storage spaceABOUT CORY SYLVESTERCory leads site selection, investment committee, and technology architecture for DXD. His innovative efforts drive the evolving proprietary technology that is core to DXD's differentiation. In addition to participating in the $53 million capital raise, Cory has built out the national real estate development team. He is a founding Principal of Radius+ and is responsible for overseeing the data validation efforts for Radius+'s core datasets. Before founding Radius+, he spent six years investing in technology companies at Columbus Circle Investors and J.P. Morgan Asset Management. He started his career at J.P. Morgan's Investment Bank after graduating with a BA in Economics from Skidmore College.CONNECT WITH CORYWebsite: DXD Capital https://www.dxd.capital/ Website: Radius+ https://radiusplus.com/ Website: Union Realtime LLC https://www.unionrealtime.com/Twitter: @hh1326 https://twitter.com/hh1326CONNECT WITH USWebsite: https://www.selfstorageinvesting.com/Facebook: https://www.facebook.com/selfstorageinvestingTwitter: https://twitter.com/SelfStorageGuyLinkedIn: https://www.linkedin.com/in/scottameyers/Youtube: https://www.youtube.com/user/SelfStorageInvestingInstagram: https://www.instagram.com/self_storage_investing/Subscribe so you never miss a NEW episode! Leave us an honest rating and review on Apple Podcast.
https://youtu.be/n3DyJQmRnq4Trending Thursday is all about stocks making news! Does the news make them worthy to buy or are you just getting caught up in the Hype? The VectorVest software can easily put things into perspective and help you make better decisions about what to do!Market OverviewSaying that the market is experiencing volatility, is an understatement! “Blood in the streets” is also an understatement! The power of the VectorVest System has never been needed as much as it is needed now! VVC, SPYRetail Stocks BustRetail got hit hard this week and weighed heavy on the market. Are these stocks still worth buying? Should we just walk away? Let us help you answer that question! LOW, HD, WMT, TGTNuclear EnergyGas prices are the highest they have ever been! People are making decisions in regards to what to do next. Electric Vehicles, Hydrogen Motors, Nuclear Energy? Let's take a look! UUUU, LTBR, BHP, DNNContra ETFsBesides energy (which I still like) Contrarian ETFs may be a play to keep your money. FAZ, SDOW, DXD, DOGUse this link for a FREE Stock Analysis Report ➥➥➥ http://bit.ly/2KsZlqzVectorVest mobile app ➥➥➥ http://bit.ly/2UjF6y6 ➥➥➥ SUBSCRIBE FOR MORE VIDEOSNever miss a daily video about making money online⇢ https://www.youtube.com/user/VectorVestMB/?sub_confirmation=1
Hey guys, welcome back to the Luminous Arts! I spend the next hour and a half talking to a good friend of mine, David Glicksman. He's the Director of Creative Technology at Gensler's DxD department in LA. They're doing some really next-level installations in some of the world's most impressive architectural projects. David's an incredibly creative guy and he's been part of the scene from the beginning. He started with VFX and motion graphics and moved into the digital placemaking industry a few years ago when he took the helm at DxD. Our conversation is great and we get into the weeds about what it means to be truly creative and an artist in this industry. I loved this conversation and I bet you will too! Links & Social Media Vimeo Instagram IMDB LinkedIn
Yes, yes!!!!! Thank goodness, I'm managing to come through on my promises for once in a damn while!Anyway, another hour (ish) long offering of spectacularly uplifting electronica for you, plus another snippet of my new project, Frankson. Please support the music and come follow me on @FranksonMusicUK across IG, FB and the Tweets.Love you endlessly...Ross xxTracklist:1. Allysha Joy 'Let It!' (First Word)2. Braxe & Falcon 'Creative Source' (Domino)3. James Greenwood 'You Control Me' (Semi Skimmed Edits)4. Laurence Guy 'Untitled Needs' (Shall Not Fade)5. Dele Sosimi Meets Medlar 'Lord Have Mercy feat. Tamar Osborn' (Wah Wah 45s)5. Blacksmith UK 'Way Back When' (All Colours Music)6. Groove Chronicles 'Joy (Brokenstep Mix)' (DPR)7. Nikitch & Kuna Maze 'La Di F… Da' (Tru Thoughts)8. Floating Points 'Vocoder' (Ninja Tune)9. Space Dimension Controller 'Mansion '96' (Tiraquon)10. Frankson, ft. Kathrin deBoer 'Mistaken (Radio Edit)' (LxL, DxD)
Here we are again...another show, another pile of wonderful new music for you guys to fall in love with, then get straight on to you beloved record store and get buying the heck out of.Plus, another snippet from my new EP, due for release on 06/05/22!Please, please, please spread the work, now more than ever!Love you...Ross. xTracklist:1. LNDFK 'Ku' (Bastard Jazz)2. Koma Saxo with Sofia Jernberg 'Croydon Koma' (We Jazz)3. Souldynamic 'Hostile Land' (Excedo)4. Fouk 'Paradise' (Shall Not Fade)5. Manolaco 'Boulevard' (Psicodelica)6. Fred Everything & Trevor Walker 'E.S.M. (Earth, Sun, Moon) (Atjazz Galaxy Aart Remix)' (Compost)7. Blindsmyth 'Connection Error (Original Mix)' (Connasseur)8. Burial + Four Tet 'Nova' (TEXT)9. Fort Romeau 'Untitled IV (Original Mix)' (Ghostly International)10.Matt Robertson 'Enveleau (Roches Noires Remix)' (Subtempo)11. Frankson 'Burning Embers' (LxL, DxD)
Chapter 2 of my high school DXD brothers of destruction book. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/jacob-wierzba/message Support this podcast: https://anchor.fm/jacob-wierzba/support
Welcome back everybody to the Self Storage Income Podcast, this is your host, AJ Osborne! It's an absolute pleasure to welcome my guest today Drew Dolan, Principal Fund Manager at DXD Capital. After earning his degree and starting a career in sales, Drew realized something…. All the guys he was working with who were in real estate had huge potential to earn a lot of money, and better yet, these same people were having a blast. Drew decided that real estate was the way forward and began working in real estate development. Fast forward to today and he's the Principal Fund Manager at DXD Capital, which is a fund that specializes in real estate development, and he's raised a total of over $600 Million across his years of experience in real estate investing and development. This was a great episode and we dive into a lot of important topics in regard to raising capital, deal structures, investor relations, and more. If you've ever thought about raising money and bringing on investors, this is an episode you won't want to miss. Keep up with Drew and DXD on their website at: https://dxd.capital/# Thanks for listening everybody! AJ The Self Storage Income Exclusive Fall Event in Coeur d'Alene Idaho (GET YOUR SEATS RESERVED ASAP!) - https://selfstorageincome.com/events/ Be sure to go to Selfstorageincome.com to get your copy of my Self Storage Playbook. This step-by-step playbook walks you through from start to finish - how to identify a self-storage market, how to perform due diligence, how to contact a current owner, and ultimately how to land a deal and purchase a storage facility. You can also find the Self Storage Income Podcast on: iTunes Spotify Stitcher The Self Storage Income Podcast is Sponsored by: Janus International - https://www.janusintl.com/ Store Local - https://www.selfstorage.coop/aws/SL/pt/sp/home_page Live Oak Bank - liveoakbank.com/incomepodcast
Welcome back everybody to the Self Storage Income Podcast, this is your host, AJ Osborne! It's an absolute pleasure to welcome my guest today Drew Dolan, Principal Fund Manager at DXD Capital. After earning his degree and starting a career in sales, Drew realized something…. All the guys he was working with who were in real estate had huge potential to earn a lot of money, and better yet, these same people were having a blast. Drew decided that real estate was the way forward and began working in real estate development. Fast forward to today and he's the Principal Fund Manager at DXD Capital, which is a fund that specializes in real estate development, and he's raised a total of over $600 Million across his years of experience in real estate investing and development. This was a great episode and we dive into a lot of important topics in regard to raising capital, deal structures, investor relations, and more. If you've ever thought about raising money and bringing on investors, this is an episode you won't want to miss. Keep up with Drew and DXD on their website at: https://dxd.capital/# Thanks for listening everybody! AJ The Self Storage Income Exclusive Fall Event in Coeur d'Alene Idaho (GET YOUR SEATS RESERVED ASAP!) - https://selfstorageincome.com/events/ Be sure to go to Selfstorageincome.com to get your copy of my Self Storage Playbook. This step-by-step playbook walks you through from start to finish - how to identify a self-storage market, how to perform due diligence, how to contact a current owner, and ultimately how to land a deal and purchase a storage facility. You can also find the Self Storage Income Podcast on: iTunes Spotify Stitcher The Self Storage Income Podcast is Sponsored by: Janus International - https://www.janusintl.com/ Store Local - https://www.selfstorage.coop/aws/SL/pt/sp/home_page Live Oak Bank - liveoakbank.com/incomepodcast
Daniella Virata is an equestrienne from a family of horse enthusiasts and competitive riders. She herself has entered several show jumping competitions around the world and earned certifications from the British Horse Society and International Federation for Equestrian Sports (FEI). A stint as a riding instructor in Singapore introduced Danni to the world of equine assisted therapy, as she worked on the Equine Assisted Learning (EQUAL) program co-developed by the Equestrian Federation of Singapore to cater to at-risk youth. Her teaching standards have been approved by the Professional Association of Therapeutic Horsemanship (PATH Int'l) and the Equine Assisted Growth and Learning Association (EAGALA). Danni comes alive when talking about all things equine, including how they've been man's partner since the dawn of civilization, and what humans can learn from these magnificent creatures. She outlines all the hard work behind the perceived glamor (think concussions, cleaning the arena, and caring for horses with colic), strides being made for inclusivity in the sport, and how she helped spearhead emergency rescue ops for 150 ponies that had to be evacuated when Taal Volcano erupted in 2020. Danni and her siblings now run DXD Equestrian Specialists, Inc., which offers group and private riding lessons, catering to aspiring competitors, adult leisure riders, and beginners. Headquartered at Rancho Leonor in Silang, Cavite (just outside Metro Manila), DXD's home base is a place to relax, enjoy nature, and appreciate the simple joys of life around animals. We hope this episode will be a breath of fresh air to animal lovers and anyone missing nature right now! Listen till the end of the episode, where we have a meditation exercise from Little Shell Yoga to soothe your spirits. --- Follow Danni's work at DXD Equestrian @dxdequestrian and @rancholeonor https://www.facebook.com/dxdequestrian Watch Danni talk about the history of horses with Ballet Philippines https://ballet.ph/en-pointe/the-virata-family/ Read more about her work and love for the sport https://ariequestrian.com/blog/2020/rider-profile-danni-virata Get a glimpse of the Mongolia trail ride she shared on the pod https://www.youtube.com/watch?v=86zQK07szZU --- Photo by @rjolaso Music: “Neon Laser Horizon” by Kevin MacLeod (imcompetech.com) licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ Sound Editing by franticsong Like what you heard? Do rate, review, share, and subscribe so others can find the episodes too. Follow instagram.com/occupationalhazards.podcast for more updates! xoxo Jo --- Send in a voice message: https://anchor.fm/occupationalhazards/message
Health Check Ep 50: Pros and cons of online doctor reviews 11:51 mins Synopsis: This is a fortnightly podcast series on Wednesdays by The Straits Times. Today's episode is on online doctor reviews. Recently, the Singapore medical council (SMC) advised doctors to refrain from participating in online search engine optimisation platforms that make use of patient feedback and ratings, as these can be considered patient testimonials. It all started when a group of doctors cried foul over not having the option to pull out of online platform DoctorxDentist (DxD) that offered reviews, in addition to health content. The start-up had listed the names of doctors it found on the SMC directory. The Singapore Medical Association and the Health Ministry subsequently got involved. DxD has since switched to an opt-in algorithm, and removed all the reviews on its platform. Although the DxD saga is over, the issue of online reviews is not. In this episode, ST senior health correspondent Joyce Teo speaks with Associate Professor Jeremy Lim, the director of global health at the National University of Singapore's Saw Swee Hock School of Public Health on the pros and cons of online doctor reviews. Listen to Pt 2 with Associate Prof Jeremy Lim on how to find the right doctor: https://omny.fm/shows/health-check-1/how-to-find-the-right-doctor-health-check-ep-51 Produced by: Joyce Teo (joyceteo@sph.com.sg), Penelope Lee and Ernest Luis Edited by: Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes fortnightly on Wednesdays and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read her stories: https://str.sg/JbxN --- Discover more ST podcast series: Asian Insider Podcast: https://str.sg/JWa7 Green Pulse Podcast: https://str.sg/JWaf ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: http://bt.sg/podcasts Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.
Health Check Ep 50: Pros and cons of online doctor reviews 11:51 mins Synopsis: This is a fortnightly podcast series on Wednesdays by The Straits Times. Today's episode is on online doctor reviews. Recently, the Singapore medical council (SMC) advised doctors to refrain from participating in online search engine optimisation platforms that make use of patient feedback and ratings, as these can be considered patient testimonials. It all started when a group of doctors cried foul over not having the option to pull out of online platform DoctorxDentist (DxD) that offered reviews, in addition to health content. The start-up had listed the names of doctors it found on the SMC directory. The Singapore Medical Association and the Health Ministry subsequently got involved. DxD has since switched to an opt-in algorithm, and removed all the reviews on its platform. Although the DxD saga is over, the issue of online reviews is not. In this episode, ST senior health correspondent Joyce Teo speaks with Associate Professor Jeremy Lim, the director of global health at the National University of Singapore's Saw Swee Hock School of Public Health on the pros and cons of online doctor reviews. Listen to Pt 2 with Associate Prof Jeremy Lim on how to find the right doctor: https://omny.fm/shows/health-check-1/how-to-find-the-right-doctor-health-check-ep-51 Produced by: Joyce Teo (joyceteo@sph.com.sg), Penelope Lee and Ernest Luis Edited by: Penelope Lee Subscribe to Health Check Podcast channel, hear the latest episodes fortnightly on Wednesdays and rate us on your favourite audio apps: Channel: https://str.sg/JWaN Apple Podcasts: https://str.sg/JWRX Spotify: https://str.sg/JWaQ Google Podcasts: https://str.sg/J6Wv Website: http://str.sg/stpodcasts Feedback to: podcast@sph.com.sg Read her stories: https://str.sg/JbxN --- Discover more ST podcast series: Asian Insider Podcast: https://str.sg/JWa7 Green Pulse Podcast: https://str.sg/JWaf ST Sports Talk Podcast: https://str.sg/JWRE Life Weekend Picks Podcast: https://str.sg/JWa2 #PopVultures Podcast: https://str.sg/JWad Bookmark This! Podcast: https://str.sg/JWas Lunch With Sumiko Podcast: https://str.sg/J6hQ Discover BT Podcasts: http://bt.sg/podcasts Follow our shows then, if you like short, practical podcasts! See omnystudio.com/listener for privacy information.
In which Cass & Alex discuss Ping Pong: The Animation, directed by Masaaki Yuasa and produced by Tatsunoko Production. Next month we will be discussing Carole and Tuesday, directed by Shinichirō Watanabe and produced by Bones. Discussed: cass and alex both liked a show for once, oh he gaming, game boy advance, neo geo pocket color (which are not black, cass was thinking of the neo geo pocket and the regular neo geo), milk gives you diabetes?, bread makes you fat?, being a connoisseur of trash, the true heady pleasure of the 100-yen bar, pips-in rubber on both sides, pips out,the defensive backspin counterpart to the offensive loop drive, what table tennis and english vocabulary have in common, let's fuckin, northernlion, buff northernlion, the virgin northernlion vs the chad northernlion, no game no life,high school DxD, code geass, a league of their own, extreme ping-pong paddle closeups, @ja2ke: "I have no memory of writing this, but there it is, in the game data.", depressing christmas montage, Spelunky 2, hundun, wonton, the undifferentiated soup of primordial chaos, 17776 by Jon Bois, it's dangerous to swim with your clothes on, that man's name? albert einstein, a 16-year-old capricorn with type-O blood, big brain hours, me absolutely twisted coming home with four ping pong robots,me waking up the next day with a room full of ping pong robots, don quijote, big steppy, table tennis is a freaking blast, english loanwords, complaining about everything being the same, 428 Shibuya Scramble, Pathologic 2, Jimmy and the Pulsating Mass, Deadly Premonition, Ode To A Moon, just hit the ball 4head, a miserable city lesbian Alex's Book Recommendation: Aquamarine by Carol Anshaw Cass's Book Recommendation: Stephen Florida by Gabe Habash Social: Show Twitter: @animeisforjerks Show Mastodon: @animeisforjerks@skeleton.cool Show Email: animeisforjerks@gmail.com Cass's Twitter: @prophet_goddess Cass's Mastodon: @prophet_goddess@skeleton.cool Alex's Twitter: @dunndunndunn Alex's Mastodon: @catalina@selfy.army
Host Piers Kicks sits down with DuckM the Co-Founder of FancyHire for Episode 03 of Metaverse Musings. His operation is one of the most fascinating early examples of how the internet can unlock extreme economic niches, and the types of behaviours we can expect to develop with the emergence of the Metaverse. In this episode, DuckM walks us through the exciting bitcoin-enabled multi-million dollar businesses that are forming around large video game economies. Join us to learn more about what it takes to build a robust international operation whose business model is the export of cheap virtual labour from struggling economies. Thank you to our sponsor Crypto.com for making this happen! Visit bit.ly/cryptodelphi for more information! - Links: FancyHire's webpage: https://fancyhire.co/https://youtu.be/-dHasR2cs9w Twitter: FancyHire's (new!) Twitter: https://twitter.com/FancyHireOSRS Piers’ Twitter: https://twitter.com/pierskicks Support the show: Delphi Podcast video interviews can be viewed here: https://youtu.be/xa7SIcET_FI Access Delphi's Research here: https://www.delphidigital.io/ Disclosures: This podcast is strictly informational and educational and is not investment advice or a solicitation to buy or sell any tokens or securities or to make any financial decisions. Do not trade or invest in any project, tokens, or securities based upon this podcast episode. The host may personally own tokens that are mentioned on the podcast. Tom Shaughnessy owns tokens in ETH, BTC, CKB, MLN, SNX, RUNE, sUSD, SOL, DXD and HNT. Lets Talk Bitcoin is a distribution partner for the Chain Reaction Podcast, and our current show features paid sponsorships which may be featured at the start, middle, and/or the end of the episode. These sponsorships are for informational purposes only and are not a solicitation to use any product or service.
The DXD podcast episode 21 w/ Mark Hinkle of Olive and Oak & The Clover and The Bee restaurant Right behind good food, hospitality comes as a close 2nd! Mark Hinkle, restaurant owner, let's us in on how his exploration within the restaurant industry have lead to the creation of his flagship Olive & Oak, the birth of The Clover and the Bee, and a slew of unique restaurants set to flood the streets of his community in Webster Groves, Missouri.
Около 500 млн рублей инвестиций планируется потратить на строительство аквапарка в Зеленоградске. Об этом и не только рассказал заместитель главы администрации Зеленоградского городского округа Павел Боровиков.
We spoke at length regarding AJ's balancing his full time career in the insurance industry and his passion project - Day by Day Jiu Jitsu company...and eventually quitting his job and pursuing his dream of building DxD.
After a week of rest and relaxation, we come back stronger than ever- sober. In the first entirely sober episode, we watch a horny ass comedy, and that's not even mentioning the demons! Join us in watching the second episode of High School DxD! Follow us @ATF_Pod Email us at animetaskforcepod@gmail.com Interstitial: Trip ~Innocent of D~ by Larval Stage Planning Ending: Style x Style by Stylips
I have really enjoyed talking with some members of the Capital One Digital Team this month, and what better way to wrap up the month than to talk about the woman who helped make all this possible -- Alana Washington! As the strategy lead on the data experience design (DXD) team at Capital One, she not only works with engineers on data visualization, but she's also building out a data journalism practice also! We talked more about Alana's work and she talked about her nontraditional path into tech, her work with organizing UX Week 2018, and the importance of fairness in artificial intelligence and machine learning for people of color. Alana also gave some great information for designers looking to enter the AI/ML space, and gave her predictions on where AI is going into the future. Thank you so much for Alana for all your hard work at Capital One, as well as helping to organize this exciting month of interviews! Alana Washington's Website Alana Washington on LinkedIn Alana Washington on Twitter Get your tickets today for "The State of the Internet 2019", a live conversation with Glitch CEO Anil Dash, Matt Mitchell of CryptoHarlem and Tactical Tech, and Maurice Cherry of Revision Path! (It's also the night of our 6th anniversary, so come out and celebrate!) For tickets, visit our event page on Eventbrite! Big thanks to Capital One for sponsoring this month of Revision Path. The Capital One Digital team is a diverse group of people who work together to build great products for the enterprise and to disrupt how people interact with their money, their bank, and their financial lives. Curious about what they're working on and how they're growing? Check them out at capitalonecareers.com or at their Medium community at medium.com/capitalonedesign. Like this episode? Then subscribe to us on Apple Podcasts, Google Podcasts, SoundCloud, Spotify, or wherever you find your favorite podcasts. Subscribe and leave us a 5-star rating and a review! Thanks so much to all of you who have already rated and reviewed us! Revision Path is brought to you by Glitch and sponsored by Facebook Design, Google Design, and Mailchimp. Powered by Simplecast. Sign up today for a 14-day free trial! You can also follow Revision Path on Facebook, Twitter, and Instagram. Come chat with us! And thanks for listening!
Nesse episódio iremos falar de animes que são quase hentai, desde o favorito Highschool DXD até os mais apelões e provocantes. E não deixe de escutar clicando no Play! Participantes: DS, Raphael, Vitor, Ly e Mayu. Pauta: Matheus Ramos Arte da Capa: DS Edição: Rafael Aguiar @aguia_rafael – Faça parte da nossa equipe! Clique Aqui! – Mande seu Recado: Email: podcast@animeunited.com.br -Links do Episódio: Twitch do DS Canal da Mayu Canal do Raul: NSV – Mundo Geek – Episódio Anterior: UNITEDcast #384 – ANIMES DA TEMPORADA DE OUTONO DE 2018
We are starting the next 200 episodes with another Listener Questions episode: Michael is 35 years old, has no debt, and $30,000 in his checking account. He contributes 3 percent of his earnings to his company’s 401(k) to gets the match. Michael wants to get more aggressive with his investments. Should he contribute more or just change out of a target date fund? John wants to understand the difference between an exchange traded note and an exchange traded fund. Also, inverse index ETFs like DXD or XQQQ, which are leveraged shorting of the NASDAQ and DOW respectively, is it not true that over time the value must degrade towards zero as markets invariably rise over long periods of time and the ETF price is designed to increase only when the index falls? Why invest in inverse ETFs? Semone feels like she can stand the volatility of the market, but wonders if it is time to increase her position with bonds in her portfolio. Jerry and his wife received a small windfall. His wife wants to pay off the car and mortgage, but Jerry thinks it’s time to invest because they have nothing saved other than a little money in a 401(k). Devin Carroll from Social Security Intelligence and the Big Picture Retirement podcast joins us to answer these questions. For more information, visit the show notes at http://moneytreepodcast.com/201
Introducing GuidedSMILE CHROME - DIGITAL, FULL-ARCH GUIDED RECONSTRUCTION GuidedSMILE was developed for dentists who desire a preplanned, predictable guided All-On-X style surgery. This amazing service delivers anchored bite verification, anchored bone reduction, anchored site drilling, accurate anchored provisionalization, and a method of transferring all surgical and restorative information for the final restorative conversion phase. Most cases simply require a CT scan and traditional records. Call to discuss your case. The process, the product, the surgery is straightforward! GuidedSMILE CHROME is a 4-Guide System 1 Pin guide - Utilizes teeth or tissue to deliver the Fixation Base (CR/CO SLM) Dentate Pin Guide is fully seated on the patient's existing dentition. Once verified via the two occlusal windows, the horizontal sites are drilled and anchored. Anchor pins are fully seated, verified and the guide is removed. Edentulous Pin Guide is a digital duplicate of the patient's existing denture. This tissue-supported guide is inserted, patient closes, and the anchor sites are drilled, anchored, verified, and the guide is removed. 2 Fixation Base - Use for bone reduction, anchoring the osteotomy guide and prosthetic Once teeth are removed and tissue is flapped, the Bone Reduction Guide is inserted, anchored, and bone is levelled to the meet the labial and lingual frame of the guide. This guide floats above the bone, and therefore should not be impinged by undercut. 3 Osteotomy Guide This guide is rigidly fixed with the pins, yet floats around the bone. Standard protocols are followed to drill sites and place implants. 4 PMMA Superior to conventional denture pick-up systems, this anchored GuidedSMILE nano-ceramic provisional transfers the CO/CR as determined by pre-surgical records. Implant abutment positions, anchor sites, tooth position, smile, and tissue space are all pre-set. 5 RAPID Appliance - The method of communicating GuidedSMILE to the articulator for the Final RAPID Appliance is ROE's special pick-up device, a clear duplicate of the PMMA. This allows the doctor to capture a second record to hold until final conversion. Once the patient is ready for the final, perform a pick-up impression, with tray adhesive on the tissue side, using medium PVS. Send this pick-up to ROE and we will GuidedSMILE Osteotomy Preparation Options Option 1 - GuidedSMILE-FG - All GuidedSMILE cases are utilize a Fully Guided Kit (as seen above) - ROE works with nearly all systems available today. Option 2 - GuidedSMILE-FH - Free-Hand - includes a location reference on the bone reduction frame to optimize implant location for PMMA pick-up, and a removeable reference inset to provide a maximum range for site preparation. Left image: notice the round divot references indicating implant general location. Right image: boundary insert used to ensure location of implants is within PMMA parameters. GuidedSMILE Work-Up Protocol Step 1: Complete our on-line Rx to provide ROE with complete case information: upload DICOM / Photograph (full face, full natural smile) as 'Documents' through this Rx web page: LINK web site portal Send master casts, bite registration (CO and/or CR), and/or digital impressions, study casts – print UPS label here. Send MSGA - Master Surgical Guide Agreement with first case (required to begin) - Required - GuidedSMILE Work Authorization required for all cases (on line or White Paper) - Optional - Esthetic & Funct'l Checklist include please if ROE is significantly changing tooth arrangement, or a new denture set-up is needed. Step 2: Meet ROE on line for implant and guide planning (allow 5 days after receiving all materials) Link Step 3: Sign and return the TPA Treatment Plan Report – via fax or scan and email Step 4: Receive the GSI Surgical Information Form to order parts and review surgery – via email Step 5: Receive guide (ROE will ship within 10 days of the signed TPA Treatment Plan Report) Notes on preparring for and capturing the CT Scan If your patient is dentate, follow the above steps, and capture a CT scan with the patient opened biting on cotton rolls. If patient is edentulous, and the existing denture fits well and the tooth arrangement is accepted, convert into a scan appliance (instructions page 6). Perform a dual scan using the protocol in our manual. If edentulous patients needs to establish tooth position and vertical, begin conventional denture steps to create a scan appliance. We are always available to discuss your case. Call 800 228 6663 and ask for the CT Department and reference GuidedSMILE. Digital Impression: ROE accepts all digital impressions. Here are your options: 3Shape - must use 3Shape Communicate - ROE's email is trios@roedentallab.com to open a connection Cadent iTero - must use Cadent's portal, just search for ROE to add connection E4D - either use the Model Export function in Romexis to export files to the desktop and upload through our portal along with your DICOM, or use DDX (not dependable) Sirona - either export a DXD file to your desktop and upload through our portal for ROE to convert, or us Cerec Connect to upload to ROE 3M TDS - must us 3M's portal Carestream 3500, 3600 - export .stl to desktop and upload to our portal, or use DDX (not dependable)
Other, Others', Hes' and Shes', welcome to Episode 38 of the Reanimetor Pod. This week Taka and Yata get together get to discuss the first series of My Hero Academia. The guys break down Episodes 1-7 and discussed the world building which takes place over these episodes. Also Taka talks DXD and doubles down on his love of Ecchi. All that and more this week on ‘Reanimetor Pod’If you like what you hear and want to get in touch please head on over to reanimetorpod.com. Scraw!! Links & Things @reanimetorpod The Site Facebook D-Mail Anime Discussed in this show Boku no Hero Academia High School DxD
A slightly technical problems show of Anime Pulse this week, with Andrew cutting in and out leaving Joseph to twiddle his thumbs. But all the internet shutting down wouldn't stop these two, as Joseph talks about the passing of his grandfather and Andrew jumps into community stuff. Only one piece of Industry News this week, and it's all about a recent episode of Darling in the Frankxx pissing off fans. Finally the previews are here, with Joseph showing his disappointment towards the new DxD and his love for the new Lupin. Andrew on the other hand is ok with a new Vampire anime, but has no time for hot guys dressing up like Butlers.
This time on Anime Hatewatch! The crew watched a show that pretends it has plot, when really it just has boobs. Character plot, boobs. Girl crying, boobs. Fight scene, boobs! Not to mention an MC who is a total horndog but can't seem to actually get any action, even when it's offered. All this, and much more on ANIME HATEWATCH! Don't forget to subscribe to us on iTunes, and while you're there leave us a rating and a review. We really appreciate it! You can check out Bloodletter at the following links: Facebook Bandcamp
Trigger warning, Red says some stuff that might piss off a select group of people. It's nothing worse than stuff Weltall or Tim have said, but still, just a fair warning. Anywho, Red and Ryo are back to the weekly grind. Red talks about Battleborn while Ryo talks about creepers at school, then Industry News brings us hot anime dads and ramen dating etiquette. As for reviews, Red exposes the giant tits in the third season of DxD and Ryo takes a torch to the sequel of Ai Mai Mii.
Sejam bem vindos a mais um UNITEDcast foderoso! Nessa semana Falaremos dele, o anime que derrotou a AT-X, o anime que faz DxD parecer um anime infantil, o Soft Porn dos animes Shinmai Maou no Testament! E para esse para esse podcast peitastico contamos com a participação de DS, Raul, Raphael,Carol. Era isso pessoas, […]
En esta nueva emision hablamos sobre los nuevos proyectos del polémico y aclamado estudio gainax ademas comentamos un poco de las segunda temporada de ore no imouto y high scool DXD y tambien en la sección gamer sobre los estrenos de las remasterizaciones de los juegos de ps2 de final fantasy mandenos sus sugerencias y pedidos musicales a nuestro email: animex-sounds@hotmail.com y en twitter como @crohononeko @srlost12
© 2020-2025 Ivy Podcast Discovery LLC
